Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab
Journal of Personalized Medicine · 19.09.2023 · 13 (9) · 1404
DOI: 10.3390/jpm13091404 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 19.09.2023. Verfasst von Giovanna Lucia Piazzetta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Otolaryngology Head and Neck Surgery, Department Medical and Surgical Sciences, University "Magna Græcia", 88100 Catanzaro, Italy. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an inflammatory disease linked to type 2 inflammation. Several biologics have demonstrated therapeutic potential for the treatment of this pathology in which IL-4, IL-5 and IL-13 represent the major cytokines involved in the control of eosinophilic respiratory inflammation. 25% of CRSwNP patients relapse after the use of oral glucocorticoids or after surgery and often require several surgeries during their lifetime. In our study we enrolled 14 patients, 11 male and 3 female. The inclusion criteria were: age ≥ 18 years; confirmed diagnosis of chronic rhinosinusitis with severe nasal polyposis; disease severity with NPS Nasal Polyposis Endoscopic Score total score ≥ 5 and/or SNOT-22 ≥ 50; previous treatment failure due to lack of efficacy or discontinuation of systemic corticosteroid therapy and/or non-response or recurrence following surgery. The results presented in this study showed the ability of Dupilumab to improve all the parameters analysed. In particular, statistically significant data were obtained for NPS, SNOT-22, NRS, and IgE in patients exposed to Dupilumab treatment for 24 weeks, highlighting the ability of Dupilumab to produce clinical benefit in CRWwNP patients. In light of these data, the administration of dupilumab every two weeks represents a valid clinical strategy that ENT specialists can adopt for the treatment of adults with inadequately controlled CRSwNP.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Otolaryngology Head and Neck Surgery, Department Medical and Surgical Sciences, University "Magna Græcia", 88100 Catanzaro, Italy.
- Laboratory of Molecular Haematopoiesis and Stem Cell Biology, Department of Experimental and Clinical Medicine, University "Magna Græcia", 88100 Catanzaro, Italy.
- Department of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.
ORCID-Profile: Emanuela Chiarella, Alberta Rizzuti, Corrado Pelaia, Girolamo Pelaia, Nicola Lombardo
Zitieren
APA
Piazzetta, G. L., Lobello, N., Chiarella, E., Rizzuti, A., Pelaia, C., Pelaia, G., & Lombardo, N. (2023). Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab. Journal of Personalized Medicine, 13(9), 1404. https://doi.org/10.3390/jpm13091404
Vancouver
Piazzetta GL, Lobello N, Chiarella E, Rizzuti A, Pelaia C, Pelaia G, et al. Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab. Journal of Personalized Medicine. 2023;13(9):1404. doi:10.3390/jpm13091404
BibTeX
@article{Piazzetta2023,
author = {Piazzetta, Giovanna Lucia and Lobello, Nadia and Chiarella, Emanuela and Rizzuti, Alberta and Pelaia, Corrado and Pelaia, Girolamo and Lombardo, Nicola},
title = {Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab},
journal = {Journal of Personalized Medicine},
year = {2023},
volume = {13},
number = {9},
pages = {1404},
doi = {10.3390/jpm13091404}
}
EUVIMED